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Abstract
Colorectal cancer (CRC) is one of the most common malignancies. Susceptibility to malignant processes is mediated by genet-
ically driven differences in the effectiveness of detoxification of potential carcinogens. One of the factors that may influence the risk of 
CRC is the glutathione-S-transferase (GST) gene family that encodes glutathione transferase enzymes. The GSTP1 gene is expressed 
both in normal and pathological conditions. Determining its specific alleles may be a marker of CRC.
The aim of the research – to study GSTP1 gene polymorphism, which is likely to be more common among patients with pri-
mary metastatic colorectal cancer compared with healthy population.
Materials and methods. The study involved 12 patients with primary metastatic colorectal cancer aged 43 to 72 years, the 
control group was represented by a sample of 31 people without cancer.
Results. The incidence of advanced CRC in the presence of GSPT1 Val/Val (aa) polymorphism is statistically significantly 
higher than in the presence of Ile/Ile (AA) and Ile/Val (Aa) GSPT1 polymorphism.
Conclusions. Among people with GSTP1 Val/Val (aa) polymorphism, primary CRC is 4.4 times more likely than among people 
with GSPT1 Ile/Ile (AA) and Ile/Val (Aa) polymorphisms, which are statistically significant (p<0.05). The obtained results indicate the 
possibility of conducting a genetic study of GSTP1 polymorphism to form groups of potential risk of CRC.
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1. Introduction
Colon cancer is one of the most common malignancies and ranks third in the list of the 
most commonly diagnosed malignancies among men and second among women. Approximately 
1.8 million first-time cases of colorectal cancer (CRC) are reported annually. According to the 
WHO GLOBOCAN database, in 2018, almost 881 thousand people died from CRC [1]. Among 
them, 24 % of patients are diagnosed with primary advanced CRC, and another 48 % of patients 
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will have metastases, which contributes to high mortality rates. According to ESMO, the 5-year 
survival rate in patients with CRC is approaching 60 % [2]. According to the National Cancer Reg-
istry of Ukraine for 2017, the incidence rate of patients with colorectal cancer in 2017 compared 
to 2016 is 5 % [3]. CRC mortality rates have been declining gradually since the mid-1980s in the 
United States and many other developed countries [4, 5]. This improvement, at least in part, may 
be related to the detection and removal of colon polyps, early-stage CRC detection, more effective 
primary and adjuvant treatments, and the improvement of instrumental and laboratory diagnostic 
methods, in particular molecular studies. Among them, those predominate that relate to the genetic 
conditioning of cancer and the pathways of carcinogenesis. The accumulated evidence suggests that 
susceptibility to malignant processes, including CRC, is mediated by genetically driven differences 
in the effectiveness of detoxification of potential carcinogens. The study of the impact of specific 
genes on the risk of CRC development is a relevant area of  research. One such factor is the fam-
ily of glutathione-S-transferase (GST) genes encoding glutathione transferase enzymes. GST are 
phase II detoxification enzymes that catalyze the conjugation  of electrophilic compounds with 
reduced glutathione, playing a central role in the cellular detoxification of various groups of exog-
enous and endogenous harmful compounds. Based on their biochemical properties, human GSTs 
are divided into α, κ, μ, ω, π, θ, ζ and microsomal classes. GST π (hereinafter – GSTP1) is often 
overexpressed in many malignant processes, including tumors of the brain, breast [6], ovaries, 
esophagus, stomach [7], pancreas, colon, skin, kidneys, lungs [8], bile ducts, lymphatic and hema-
topoietic systems. GST gene polymorphism can influence the risk of CRC by modifying the effects 
of carcinogenic food-related agents on the intestinal mucosa .  The GSTP1 gene is expressed as 
normal and pathological, however, the determination of its specific alleles can be a marker of CRC. 
According to existing studies, an increase in the level of the GSTP1 enzyme in tumors of the colon 
may indicate high resistance to anticancer drugs [9, 10].
The aim of the research – to study GSTP1 gene polymorphism, which is likely to be 
more common among patients with primary metastatic colorectal cancer compared with healthy 
population.
2. Materials and methods of the research
The study involved 12 patients with newly diagnosed metastatic colorectal cancer aged 43 
to 72 years (mean age 65.1 years) who underwent special treatment at the University Clinic of 
Odessa National Medical University from January to August 2019. Diagnosis in all patients was 
confirmed histologically and immunohistochemically; the spread of the process was determined 
intraoperatively and by methods of preoperative intrascopic examinations. In assessing GSTP1 
gene polymorphism, the control group was represented by a sample of 31 people without onco-
pathology (mean age 62.3 years) living in Odessa. The nuclear material of patients’ leukocytes of 
venous blood was studied. Samples were presented by patients of Ukrainian nationality. 
The GSTP1 gene is characterized by a number of polymorphisms, the most common is the 
105Ile/Val polymorphism in the fifth exon and 114Ala / Val in the sixth exon [11]. The 105Ile/Val 
polymorphism is associated with the single-nucleotide substitution of 313 A>G and relates to a hy-
drophobic substrate binding site that has a significant effect on the course of biochemical reactions. 
The Val variant three times reduces the detoxification activity of the enzyme against xenobiot-
ics. EX5-1 5′-GTAGTTTGCCCAAGGTCAAG-3′ primers starting from 2306 nucleotide pairs of 
the complete GSTP1 sequence and EX5-2 5′-AGCCACCTGAGGGGTAAG-3′ primers starting at 
2721 nuclei were used to amplify the polymorphic version of exon 5. 8 μl of isolated DNA was 
added to a polymerase chain reaction (PCR) mixture containing 0.5 U Taq-polymerase, 11 pmol of 
each primer, 1.5 μl of 10 ‘PCR buffer (25 mm MgCl2) and 2.5 μl of 10hdNTPmix in a final volume 
of 15 μl. “Hot Start” was used to prevent nonspecific priming in the first PCR cycle. After initial 
denaturation for 12 min at 95 °C, the following 15 cycles of PCR were performed (denaturation for 
30 s at 95 °C, annealing for 30 s at 58 °C, elongation for 60 s at 72 °C), followed by 25 cycles ampli-
fication (denaturation for 30 s at 95 °C, annealing for 30 s at 55 °C, elongation for 60 s at 72 °C) and 
one elongation cycle at 72 °C for five minutes. PCR products were cut for two hours at 37 °C with 
five units of Alw26I (Fermentas Inc, Vilnius, Lithuania). During 2 % agarose gel electrophoresis 
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in the presence of the 105Ile allele in the homozygous state, fragments of size 329 and 104 pairs of 
nucleotides are observed, in the presence of the allele 105Val in the homozygous state, fragments 
in the size of 222 and 107 nucleotide pairs, in heterozygotes – all four DNA fragments (Fig. 1). 
Fig. 1. Electrophoregram of human DNA samples containing the 105Ile/Val polymorphism of  
the GSTP1 gene: 1 – molecular steps; 2 – homozygote 105Ile/Ile; 3 – heterozygote 105Ile/Val;  
4 – homozygote 105Val/Val.
The study was conducted within the framework of joint scientific work of the Depart-
ment of Surgery No. 4 with the oncology course and the Department of Medical Biology of the 
Odessa National Medical University. Compliance with the World Medical Association Code 
of Ethics WMA Declaration of Helsinki – Ethical Principles for Medical Research Involving 
Human Subjects, 2013 (minutes of the meeting of the Committee on Bioethics of the Odessa 
National Medical University No. 123A dated 29.08.2019) was determined. All study partici-
pants were informed and agreed to the processing of their clinical data and to participate in 
the research process.
The statistical analysis of the data obtained was performed using GNU PSPP version 1.2.0 
using Fisher’s two-sided exact P test.
3. Results
The incidence of GSTP1 gene polymorphism among CRC patients and controls was pre-
sented in Table 1.
Table 1
The incidence of GSTP1 gene polymorphism among CRC patients and control group
Genotypes Ile/Ile (AA) Ile/Val (Aa) Val/Val (aa)
Patients 
n=12 4 (33.33 %) 2 (16.67 %) 6 (50.00 %)
Control 
n=31 17 (54.84 %) 12 (38.71 %) 2 (6.45 %)
According to Table 1, in the sample of patients with initially diagnosed metastatic 
CRC homozygotes for the Val allele were in 6 (50.00 %) studied, while in the control group in 








Tables 2–4 present a comparison of the frequency of occurrence of GSTP1 Ile/Ile (AA) 
polymorphism with Ile/Val (AA)+Val/Val (AA), Ile/Val (AA) with Ile/Ile (AA)+Val/Val (aa) and 
Val/Val (aa) with Ile/Ile (AA)+Ile/Val (AA) respectively in patients with initially diagnosed meta-
static CRC and in the control group, statistical significance using Fisher’s two-sided exact P test, 
and also the significance of the RR relationship (95 % CI). 
Table 2
Comparison of the incidence of GSTP1 Ile/Ile (AA) polymorphism with Ile/Val (AA)+Val/Val (AA) among 
CRC patients and control group
Genotypes Ile/Ile (AA) Ile/Val (Аа)+Val/Val (аа)
Patients 
n=12 4 (33.33 %) 8 (66.67 %)
Control 
n=31 17 (54.84 %) 14 (45.16 %)
Fisher’s P-test 0,31015 (р=0.05)
RR (95 % CI) 0.524 (0.185–1.483)
According to the results in Table 2, the Fisher P-test, which was determined when calcu-
lating the incidence of Ile/Ile (AA) polymorphism compared with Ile/Val (Aa) and Val/Val (aa) in 
patients with metastatic CRC and in the control group was 0.31015, thus Fisher’s P-test>0.05. The 
incidence of advanced CRC in the presence of GSPT1 Ile/Ile (AA) polymorphism is lower than in 
the presence of GSPT1 Ile/Val (AA)+Val/Val (AA) polymorphism, but the difference is not statis-
tically significant. The relative risk indicator is 0.524 at 95 % CI (0.185–1.483). The significance 
level of this relationship is greater than 0.05, since 95 % CI includes one, so reducing the likelihood 
of primary metastatic CRC with GSPT1 Ile/Ile (AA) is not statistically significant.
According to the results given in Table 3, which were determined when calculating the in-
cidence of polymorphism Ile/Val (AA) compared with Ile/Ile (AA)+Val/Val (AA) in patients with 
CRC and in the control group was 0.27852, thus Fisher’s P-test>0.05. The incidence of metastatic 
CRC in the presence of the Ile/Val (AA) polymorphism is lower than in the presence of the GSPT1 
Ile/Val (AA)+Val/Val (AA) polymorphism, but the difference is not statistically significant. The 
relative risk indicator is 0.414 at 95 % CI (0.104–1.643). The significance level of this relationship 
is greater than 0.05, since 95 % CI includes one, so reducing the likelihood of primary diagnosed 
metastatic CRC with GSPT1 Ile/Val (AA) is not statistically significant.
Table 3
Comparison of the incidence of GSTP1 Ile/Val (AA) polymorphism with Ile/Ile (AA)+Val/Val (AA) among 
CRC patients and control group
Genotypes Ile/Val (Aа) Ile/Ile (АА)+Val/Val (аа)
Patients 
n=12 2 (16.67 %) 10 (83.33 %)
Control 
n=31 12 (38.71 %) 19 (61.29 %)
Fisher’s P-test 0.27852 (р=0,05)
RR (95 % CI) 0.414 (0.104–1.643)
According to the results in Table 4 Fisher’s P-test, which was determined when calculating 
the frequency of occurrence of Ile/Ile (AA) and Ile/Val (Aa) polymorphism in comparison with 
Val/Val (aa) in patients with CRC and in the control group was 0.00314, that is, the value of 
the Fisher P-test<0.05. The incidence of advanced CRC in the presence of GSPT1 Val/Val (aa) 
polymorphism is statistically significantly higher than in the case of GSPT1 Ile/Ile (AA) and 
Ile/Val (Aa) polymorphism. 
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Comparison of incidence of GSTP1 Val/Val (aa) polymorphism with Ile/Ile (AA)+Ile/Val (AA) among CRC 
patients and controls
Genotypes Val/Val (аа) Ile/Ile (АА)+Ile/Val (Аа)
Patients 
n=12 6 (50.00 %) 6 (50.00 %)
Control 
n=31 2 (6.45 %) 29 (93.55 %)
Fisher’s P-test 0.00314 (р=0,05)
RR (95 % CI) 4.375 (1.906–10.043)
According to the calculations in Table 4, the relative risk indicator for the presence of 
GSTP1 Val/Val (aa) polymorphism is 4.375 at 95 % CI (1.906–10.043). This indicates that there 
is a direct relationship between the presence of GSTP1 Val/Val (aa) polymorphism and the like-
lihood of developing metastatic CRC. Among people with GSTP1 Val/Val (aa) polymorphism, 
primary-spread CRC is 4.375 times more likely than among people with GSPT1 Ile/Ile (AA) and 
Ile/Val (Aa) polymorphism. The significance level of this relationship corresponds to p<0.05, since 
95 % CI does not include one. 
4. Disscussion
Epidemiological studies indicate that individuals with the expression of different alleles of 
the GSTP1 gene are susceptible to chemical carcinogens, because polymorphism of the GSTP1 
gene can cause changes in the expression or structure of the enzyme, leading to a decrease in the 
efficiency of the catalytic function of variants of the enzyme, ie, insufficient detoxification of car-
cinogens and, therefore, affect the development of CRC. GSTP1 is expressed normally in epithelial 
tissue, but there are works on its overexpression in colon cancer [12]. Functional polymorphism of 
the GSTP1 gene, which reduces enzymatic activity, involves the replacement of A-G in 5 exons 
and the conversion of isoleucine to valine at position 105 of the amino acid chain (Ile105Val) [13]. 
In Rodrigues-Fleming GH et al., 2018, GST genes were studied in patients with sporadic colorectal 
cancer, identifying a direct relationship between the presence of the wild-type GSTP1 Ile105Val 
polymorphism and the smoking risk of CRC [14]. Carriers of these mutations have a reduced de-
toxification function of the enzyme in relation to carcinogens, so there is an increased risk of a 
malignant process [11, 15]. 
In the study, we identified a possible correlation of common GSTP1 polymorphism with 
the presence of primary advanced CRC. The distribution of the GSPT1 genotype among patients 
was Ile/Ile (AA) 33.33 %, Ile/Val (AA) 16.67 % and Val/Val (AA) 50.0 %, whereas in the control 
group Ile/Ile (AA) 54.84 %, Ile/Val (AA) 38.71 % and Val/Val (AA) 6.45 % (Table 1). In contrast 
to the described results, in the work of Gorukmez O. et al., 2016, the GSTP1 Ile/Ile (AA) gene poly-
morphism was more common in CRC patients, and the Ile/Val (AA) and Val/Val (AA) genotypes 
were more common in the control group [12]. When comparing the incidence of GSPT1 Val/Val (aa) 
polymorphism with Ile/Ile (AA)+Ile/Val (AA) polymorphisms, the obtained results indicate that 
there is a direct relationship between GSPT1 Val/Val (aa) polymorphism and the probability of pri-
mary diagnosed metastatic CRC (Table 4). The incidence of advanced CRC in the presence of GSPT1 
Val/Val (aa) polymorphism is statistically significantly higher than in the presence of Ile/Ile (AA) 
and Ile/Val (Aa) GSPT1 polymorphism. Among people with GSTP1 Val/Val (aa) polymorphism, 
primary diagnosed CRC is 4.375 times more likely than among people with GSPT1 Ile/Ile (AA) 
and Ile/Val (Aa) polymorphisms, which are statistically significant (p<0.05) (Table 4). Similar results 
were obtained in the study by Khabaz M. N. et al., 2016, the incidence of the GSPT1 Val/Val (aa) 
genotype in colorectal cancer cases was three times higher than in the control groups, but the re-
sults were not statistically significant [16]. In contrast, in the study of GSTP1 polymorphism and 
the risk of colorectal cancer among the Polish population, the genotype frequency of Ile/Ile (AA), 
Ile/Val (Aa) and Val/Val (AA) was respectively 42.1 %, 48.2 %, 9.6 % in patients and 48.1 %, 
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42.3 % and 9.6 % in control groups [17]. In another study of GSTP1 gene polymorphism in an eth-
nic Kashmiri population, a homozygous variant of the Val/Val (aa) genotype was associated with 
an increased risk of CRC [18]. In the study of GSTP1 polymorphism in the Tunisian population, 
a direct correlation of the homozygous variant of the Val/Val (aa) genotype with the incidence of 
CRC was also identified [19].
In contrast, the results of the Cong N et. al, 2014 in the Chinese population showed no asso-
ciation between GSTP1 Val/Val (aa) polymorphism and CRC risk [20].
Study limitations. The main limitation of the study is the identification of GSTP1 gene 
polymorphism in this sample, not taking into account the possible presence of other genetic muta-
tions associated with the risk of CRC. In addition, despite the statistically reliable data obtained, an 
increase in the sample size and the distribution of patients into different subgroups by gender and 
age would allow to obtain data that are more accurate. 
Prospects for futher research. In the future, it is planned to analyze the dependence of 
GSTP1 gene polymorphism and the results of special treatment (combination treatment in the form 
of cytoreductive surgery and subsequent adjuvant PCT and exclusively PCT) in patients with ini-
tially diagnosed CRC, based on an assessment of the duration of their disease-free period and over-
all survival. It is also planned to study the correlation of the degree of differentiation of CRC with 
polymorphisms of the GSTP1 gene.
5. Conclusions
In this study, genetic factors that can play a significant role in the pathogenesis of CRC are 
analyzed. According to the analyzed data, among people with GSTP1 Val/Val (aa) polymorphism, 
the primary diagnosed metastatic CRC is statistically significantly more frequent than among peo-
ple with GSPT1 Ile/Ile (AA) and Ile/Val (Aa) polymorphisms. The obtained results indicate the 
possibility of conducting a genetic study of GSTP1 polymorphism to form groups of potential risk 
of CRC. Understanding the role of GST gene polymorphism and their interaction with other factors 
in the process of carcinogenesis can improve the tactics of diagnosis and prevention of various 
types of malignant processes. Thus, our findings provide the basis for future epidemiological and 
clinical studies.
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